Core Insights - Haisheng Pharmaceutical (stock code: 870656) reported a strong performance in the first half of 2025, achieving revenue of 101 million yuan, a year-on-year increase of 42.14%, and a net profit of 30.33 million yuan, up 29.33% [2][3] - The company focuses on core businesses including veterinary drug raw materials, pharmaceutical raw materials, and intermediates, which contributed to double-digit growth in both revenue and profit [2][3] Business Performance - The raw material drug segment remains the main growth driver, generating revenue of 77.94 million yuan, a 58.14% increase, with a gross margin of 43.81% [3] - The intermediates segment achieved revenue of 22.71 million yuan, reflecting a 5.46% growth [3] - Domestic market revenue reached 78.44 million yuan, a 64.35% increase, benefiting from rising demand in the downstream aquaculture industry, with a gross margin of 39.70% [3] - The overseas market faced challenges due to exchange rate fluctuations and international competition, resulting in revenue of 22.41 million yuan, a decline of 3.51%, but maintaining a high gross margin of 56.34% [3] Research and Development - R&D expenses for the first half of 2025 amounted to 5.21 million yuan, a 28.68% increase, focusing on process optimization and new product development for raw materials and intermediates [3] - Ongoing capacity expansion projects, including the 200-ton Celecoxib upgrade and 150-ton Tranexamic Acid production, are progressing well, with some projects entering equipment debugging stages [3] Compliance and Environmental Responsibility - The company adheres strictly to safety and environmental regulations, with no major incidents reported during the reporting period [4] - A comprehensive waste treatment system is in place, ensuring compliance with national and local environmental standards [4] Future Outlook - Haisheng Pharmaceutical plans to continue focusing on core businesses, accelerate project construction, and expand both domestic and emerging overseas markets to achieve steady annual growth [4] - The company aims to leverage its technological accumulation, capacity reserves, and compliance advantages to strengthen its market position amid ongoing industry expansion and recovering downstream demand [4]

Group 1: Company Performance - During the first half of 2025, the company achieved operating revenue of 101 million yuan, a year-on-year increase of 42.14% [1] - The total profit reached 35 million yuan, reflecting a year-on-year growth of 29.72% [1] - The net profit attributable to shareholders was 30 million yuan, with a year-on-year increase of 29.33% [1] Group 2: Competitive Advantages - The company is a significant supplier of sulfonamide drugs globally, with a long product chain and self-production of key intermediates, which mitigates supply shortages [1] - The company has a strong position in the veterinary raw materials market, with its core product SPDZ showing high sales revenue [2] - The company employs a flexible production model based on sales, enhancing market adaptability and resilience to cyclical fluctuations [2] Group 3: Market Trends - The global veterinary drug market is projected to grow from approximately 44.59 billion USD in 2022 to about 83.76 billion USD by 2030, with a compound annual growth rate (CAGR) of 8.2% [2] - The domestic veterinary drug market is expected to expand from 68.62 billion yuan in 2021 to 139.57 billion yuan by 2027, with a CAGR of 12.56% [3] - The company is focusing on expanding its product offerings in both sulfonamide and non-sulfonamide raw materials, as well as pet medications [3] Group 4: Shareholder Returns - The company implemented a high cash dividend and stock transfer plan, distributing 20 million yuan in cash dividends and increasing its total share capital to 100 million shares [4] - This initiative reflects the company's strong profitability and commitment to shareholder returns [4]

Core Insights - Haisheng Pharmaceutical (870656.BJ) released its semi-annual report for 2025 on August 21, 2025, indicating a total of 8 institutional investors holding shares in the company [1] - The total shareholding by institutional investors reached 4.27% of Haisheng Pharmaceutical's total equity, amounting to 4.2697 million shares [1] - Compared to the previous quarter, the proportion of shares held by institutional investors increased by 0.45 percentage points [1] Institutional Holdings - Eight institutional investors disclosed their holdings in Haisheng Pharmaceutical A-shares [1] - The institutional investors include Qizhou Youming Enterprise Management Partnership (Limited Partnership), clients of Kaiyuan Securities Co., Ltd., clients of China International Capital Corporation Wealth Securities Co., Ltd., and Shandong Yixing Venture Capital Co., Ltd. [1] - The cumulative holding ratio of institutional investors rose to 4.27% from the previous quarter [1]

长江证券承销保荐有限公司关于浙江海昇药业股份有限 公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》 等有关法律法规、规范性文件等的规定，长江证券承销保荐有限公司（以下简称 "保荐机构"）作为浙江海昇药业股份有限公司（以下简称"海昇药业""公司"） 的保荐机构，负责海昇药业的持续督导工作，并出具 2025 年半年度持续督导跟 踪报告。 一、持续督导工作概述 （一）审阅公司信息披露文件情况 保荐机构查阅公司募集资金使用台账、募集资金专户银行对账单，了解募投 项目实施进度并实地查看募投项目进展情况；获取公司购买理财产品的协议及相 关凭证，核查公司使用闲置募集资金进行现金管理是否符合法律规定；及时审阅 募集资金信息披露相关文件等。 （四）督导公司规范运作情况 对于公司重要信息披露文件，如定期报告、董事会决议、股东会决议、权益 分派等公告文件，保荐机构均履行了事前审阅程序。 （二）督导公司建立健全并有效执行规则制度情况 保荐机构已督导公司按照法律、法规、部门规章和相关业务规则及其他规范 性文件的要求健全并有效执行规则制度。报告期内，公司相关规章制度有效执行。 ...

证券代码：870656 证券简称：海昇药业 公告编号：2025-109 浙江海昇药业股份有限公司 2025 年半年度募集资金存放、管理与实际使用情况的 专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 （一）实际募集资金净额、资金到位时间 根据中国证券监督管理委员会《关于同意浙江海昇药业股份有限公司向不 特定合格投资者公开发行股票注册的批复》（证监许可〔2024〕1 号），本公司 由主承销商长江证券承销保荐有限公司和联席主承销商甬兴证券有限公司采 用向战略投资者定向配售和网上向开通北京证券交易所交易权限的合格投资 者定价发行相结合的方式，向不特定合格投资者公开发行人民币普通股股票 2,000 万股，发行价为每股人民币 19.90 元，共计募集资金 39,800.00 万元， 扣除承销和保荐费用 3,085.00 万元后的募集资金为 36,715.00 万元，已由主 承销商长江证券承销保荐有限公司于 2024 年 1 月 26 日汇入本公司募集资金监 管账户。另减除上网发行费 ...

证券代码：870656 证券简称：海昇药业 公告编号：2025-110 1.会议召开时间：2025 年 8 月 21 日 2.会议召开地点：衢州市高新技术产业园区华阳路 36 号会议室 3.会议召开方式：现场方式 浙江海昇药业股份有限公司 4.发出董事会会议通知的时间和方式：2025 年 8 月 11 日以书面方式发出 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本议案已经公司第四届董事会审计委员会第二次会议审议通过。 会议应出席董事 5 人，出席和授权出席董事 5 人。 二、议案审议情况 （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 1.议案内容： 5.会议主持人：董事长叶山海先生 具体内容详见公司于 2025 年 8 月 21 日在北京证券交易所信息披露网站 6.会议列席人员：公司副总经理、董事会秘书彭红江 （www.bse.cn）披露的《2025 年半年度报告》（公告编号：2025-107）、《20 ...

证券代码：870656 证券简称：海昇药业 公告编号：2025-106 浙江海昇药业股份有限公司 关于使用部分闲置募集资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 1．上年授权现金管理 浙江海昇药业股份有限公司（以下简称"公司"）于 2024 年 5 月 16 日召开 第三届董事会第十六次会议、第三届监事会第十五次会议，于 2024 年 6 月 3 日召开 2024 年第二次临时股东会议，审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》，在确保资金安全、不影响募集资金投资项目建设的前提 下，公司拟使用额度不超过人民币 3 亿元（含本数）的闲置募集资金进行现金 管理，在上述额度范围内资金可以循环滚动使用，并授权公司董事长行使相关 投资决策权并签署相关文件，财务负责人负责具体组织实施及办理相关事宜。 具体内容详见公司在北京证券交易所信息披露平台（www.bse.cn）披露的《关 于使用部分闲置募集资金进行现金管理的 ...

证券代码：870656 证券简称：海昇药业 公告编号：2025-105 浙江海昇药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 （一）已授权委托理财基本信息 （二）本次委托理财披露的标准 根据《北京证券交易所股票上市规则》中相关规定，交易的成交金额占上市 公司最近一期经审计净资产的 10%以上且超过 1,000.00 万元的应当予以披露。 本次自有资金购买的理财产品金额为 4,300 万元，截至目前，公司自有资金 购买的理财产品未到期余额为 10,460 万元。 二、 本次委托理财情况 | 受托方 | 产品类 | | 产品名称 | 产品金 额（万 | 预计年化收 | 产品期 | 收益 | 投资 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 型 | | | 元） | 益率（%） | 限 | 类型 | 方向 | 来源 ...

（一）公司基本情况 （二）执业评价情况 （1）信披情况： （6）发行费用及发行费用率 海昇药业的承销及保荐费用为3185.00万元，承销保荐佣金率8.00%，高于整体平均数7.71% 。 （7）上市首日表现 问询轮数超三轮；全面梳理"重大事项提示""风险因素"各项内容，突出重大性，增强针对性，强化风险 导向，删除针对性不强的表述；发行人未披露报告期内细分产品构成及终端应用领域情况。 （2）监管处罚情况： 2023年5月5日因重大交易违规被全国股转公司口头警示；2023年6月因信披违规被浙江证监局出具警示 函。 （3）舆论监督：不扣分 （4）上市周期：不扣分 2024年度已上市A股企业从申报到上市的平均天数为629.45天，海昇药业的上市周期是280天，低于整体 均值。 （5）是否多次申报：不属于，不扣分 （11）上市后短期业绩表现 2024年，公司营业收入较上一年度同比下降22.73%，归母净利润较上一年度同比下降40.12%，扣非归 母净利润较上一年度同比下降48.10%。 上市首日股价较发行价格上涨0.00%。 （8）上市三个月表现 全称：浙江海昇药业股份有限公司 简称：海昇药业 代码：870656.BJ ...

Market Overview - As of July 24, the Shanghai Composite Index closed at 3605.73 points, up 23.43 points, with a gain of 0.65% [1] - The Shenzhen Component Index closed at 11193.06 points, up 134.02 points, with a gain of 1.21% [1] - The ChiNext Index closed at 2345.37 points, up 34.70 points, with a gain of 1.50% [1] Trading Activity - A total of 101 A-shares had a turnover rate exceeding 20% on July 24 [1] - Notable stocks with high turnover rates included: - C Jiyuan (603262) with a turnover rate of 58.79% and a closing price of 38.67 CNY, down 5.10% [1] - C Shanda (301609) with a turnover rate of 55.61% and a closing price of 60.79 CNY, down 9.07% [1] - Shen Nong Agriculture (300189) with a turnover rate of 53.68% and a closing price of 5.47 CNY, up 19.96% [1] - Hengli Drill (836942) with a turnover rate of 50.38% and a closing price of 56.19 CNY, up 29.98% [1] Notable Stocks - Other significant stocks with high turnover rates included: - Zhongshe Co. (002883) with a turnover rate of 49.68% and a closing price of 16.79 CNY, up 10.03% [1] - Yongda Co. (001239) with a turnover rate of 47.19% and a closing price of 19.41 CNY, down 7.88% [1] - Nankuang Group (001360) with a turnover rate of 47.09% and a closing price of 18.71 CNY, down 9.96% [1] - Guanlong Energy (301151) with a turnover rate of 46.56% and a closing price of 24.47 CNY, up 1.49% [1] Additional Insights - The trading data indicates a significant level of activity in the market, with several stocks experiencing notable price movements and turnover rates [1][2][3][4]